Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Antibodies; Immunoglobulin A; Immunoglobulins; Ramipril

Criteria

Inclusion Criteria:

• biopsy-confirmed IgA nephropathy

• proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 µmol/l

Exclusion Criteria:

• pregnant or nursing mother, or women of childbearing potential without an effective method of birth control

• history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor

• evidence of clinically significant hepatic, gastrointestinal, autoimmune disease

• history of malignancy, drug or alcohol abuse

• participation in any previous trial on ACE inhibitor

• taking other investigational drugs within the past 30 days

• known history of sensitivity / allergy to ACE inhibitor

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.